Tyra Biosciences, Inc. (TYRA) Latest Stock News & Headlines
Get the latest Tyra Biosciences, Inc. (TYRA) stock news and headlines to help you in your trading and investing decisions.
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History ...
Find the latest Tyra Biosciences, Inc. (TYRA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Tyra Biosciences, Inc. (TYRA) Stock Price, Quote & News - Stock …
Jan 17, 2025 · Get a real-time Tyra Biosciences, Inc. (TYRA) stock price quote with breaking news, financials, statistics, charts and more.
Tyra Looks to Challenge J&J’s Balversa With Early Data for FGFR3 ...
Oct 25, 2024 · Tyra Biosciences on Thursday unveiled early proof-of-concept data for its investigational and potential first-in-class FGFR3 inhibitor TYRA-300, touting “encouraging” anti-tumor action in heavily pretreated patients with metastatic urothelial carcinoma.
Tyra Biosciences Receives IND Clearance from FDA to Proceed …
Oct 28, 2024 · TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4.
News Releases - Tyra Bio Investor Relations
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
Tyra Biosciences, Inc. (TYRA) Latest Stock News | Seeking Alpha
Get the latest news and real-time alerts from Tyra Biosciences, Inc. (TYRA) stock at Seeking Alpha.
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA …
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
Tyra Biosciences Doses First Patient with TYRA-200 and Provides ...
Dec 22, 2023 · TYRA initiated the SURF201 study and has dosed the first patient with TYRA-200, an FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations.
News & Press | Tyra Biosciences
Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology. Mar 31, 2021.